References
- Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000; 35(4 Suppl 1): S97–105
- Kasiske BL, Keane WF. Laboratory assessment of renal disease: clearance, urinalysis, and renal biopsy. In: Brenner BM, Rector FC, eds. Brenner and Rector's the kidney. Vol 1. 6th ed. Philadelphia: WB Saunders, 2000: 1129–70
- Tencer J, Torffvit O, Thysell H, et al. Proteinuria selectivity index based upon alpha 2-macroglobulin or IgM is superior to the IgG based index in differentiating glomerular diseases. Technical note. Kidney Int 1998; 54(6): 2098–105
- Hebert L. Glomerular diseases: The American College of Physicians Nephrology Medical Knowledge Self Assessment Program (MKSAP). Philadelphia: American College of Physicians—American Society of Internal Medicine, 1998
- Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999; 33(5): 1004–10
- Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprotection: one or many therapies? Kidney Int 2001; 59(4): 1211–26
- Wilmer WA, Hebert LA, Lewis EJ, et al. Remission of nephrotic syndrome in type 1 diabetes: long-term follow-up of patients in the Captopril Study. Am J Kidney Dis 1999; 34(2): 308–14
- The African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001; 285(21): 2719–28
- Chapman AB, Johnson AM, Gabow PA, et al. Overt proteinuria and microalbuminuria in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1994; 5(6): 1349–54
- Klahr S, Levey AS, Beck JG, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 1994; 330(13): 877–84
- Bakris GL, Williams M, Dworkin L, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 2000; 36(3): 646–61
- Goligorsky MS. Endothelial cell dysfunction and nitric oxide synthase. Kidney Int 2000; 58(3): 1360–76
- Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, oncardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342(3): 145–53
- Ruggenenti P, Perna A, Mosconi L, et al. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997; 349(9069): 1857–63
References
- Klahr S, Levey AS, Beck JG, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med. 1994, 330(13): 877–84
- Hebert LA, Wilmer WA, Falkenhain ME, et al. Renoprorection: one or many therapies? Kidney Int 2001; 59(4): 1211–26
- Roubicek C, Brunet P, Huiarr L, et al. Timing of nephrology referral influence on mortality and morbidity. Am J Kidney Dis 2000; 36(1): 35–41